Israeli heart valve maker Mvalve reportedly pulls in a $15 million investment from Boston Scientific in a deal that includes a $200 million buyout option.
Boston Scientific (NYSE:BSX) reportedly put down a $15 million investment in Israeli heart valve developer Mvalve Technologies that includes a $200 million buyout option.
Mvalve is developing technology to treat mitral valve regurgitation, according to its LinkedIn profile. Co-founder & CEO Assif Stoffman is an executive vice president with Israeli venture capital fund XT Hitech, which is the sole investor in Mvalve, according to Globes.
Hey, check out all the research scientist jobs. Post your resume today!
